Quick Answer
Arbutus Biopharma Corp reported Stockholders Equity of $76.58 million for the year ending 2025.
- Arbutus Biopharma Corp showed a decrease of -21.4% in Stockholders Equity from 2024 to 2025.
- This data is from Arbutus Biopharma Corp's annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $105.48 million | Q2 2014: $105.15 million | Q3 2014: $95.50 million | Q1 2015: $593.69 million | Q2 2015: $588.50 million | Q3 2015: $553.81 million | Q1 2016: $538.08 million | Q2 2016: $431.32 million | Q3 2016: $416.63 million | Q1 2017: $189.10 million | Q2 2017: $175.79 million | Q3 2017: $167.39 million | Q1 2018: $232.42 million | Q2 2018: $238.07 million | Q3 2018: $215.27 million | Q1 2019: $181.21 million | Q2 2019: $164.47 million | Q3 2019: $83.64 million | Q1 2020: $73.26 million | Q2 2020: $65.51 million | Q3 2020: $97.35 million | Q1 2021: $114.15 million | Q2 2021: $100.83 million | Q3 2021: $130.14 million | Q1 2022: $165.85 million | Q2 2022: $153.14 million | Q3 2022: $145.52 million | Q1 2023: $143.92 million | Q2 2023: $134.69 million | Q3 2023: $119.34 million | Q1 2024: $114.64 million | Q2 2024: $122.45 million | Q3 2024: $106.89 million | Q1 2025: $79.16 million | Q2 2025: $82.98 million | Q3 2025: $77.40 million.
- Over the full 16 years of available data (2010 to 2025), Arbutus Biopharma Corp's Stockholders Equity has grown by 613.5%.
- Historical annual values: Fiscal year 2025: $76.58 million | Fiscal year 2024: $97.37 million | Fiscal year 2023: $106.02 million | Fiscal year 2022: $136.85 million | Fiscal year 2021: $169.44 million | Fiscal year 2020: $101.97 million | Fiscal year 2019: $72.74 million | Fiscal year 2018: $200.23 million | Fiscal year 2017: $182.47 million | Fiscal year 2016: $203.01 million | Fiscal year 2015: $547.68 million | Fiscal year 2014: $88.04 million | Fiscal year 2013: $59.19 million | Fiscal year 2012: $40.92 million | Fiscal year 2011: $5.23 million | Fiscal year 2010: $10.73 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: